Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 14Carcinoma, Non-Small-Cell Lung 5Prostatic Neoplasms 4Lung Neoplasms 3Stomach Neoplasms 2Esophageal Neoplasms 2Breast Neoplasms, Male 2Uterine Neoplasms 1Thrombosis 1Peritoneal Neoplasms 1Pathological and Imaging Examinations Confirmed Metastatic Prostate Cancer 1Pancreatic Neoplasms 1Non-squamous Non-small Cell Lung Cancer 1Non-Muscle Invasive Bladder Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1NSCLC 1Inflammatory Breast Neoplasms 1Infections 1Hypopharyngeal Neoplasms 1Hormone Refractory Prostate Cancer 1Head and Neck Neoplasms 1Esophageal Squamous Cell Carcinoma 1Drug-Related Side Effects and Adverse Reactions 1Carcinogenesis 1Breast Neoplasm Female 1Breast Diseases 1Amenorrhea 1Adenocarcinoma 1

Interventions

anlotinib 3Pemetrexed 2endostar protein 1Gefitinib 1Docetaxel 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Non-squamous Non-small Cell Lung Cancer × Docetaxel × Clear all
NCT03566576 2018-06-25

Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel

Fujian Cancer Hospital

Phase NA Unknown
18 enrolled
Thoracic

Non-squamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡